Zobrazeno 1 - 10
of 128
pro vyhledávání: '"Jeremy P, Segal"'
Autor:
Gregory W. Roloff, Frank Wen, Aubrianna Ramsland, Andrew S. Artz, Satyajit Kosuri, Wendy Stock, Olatoyosi Odenike, Richard A. Larson, Hongtao Liu, Lucy A. Godley, Michael J. Thirman, Anand A. Patel, Christopher K. Daugherty, Adam S. DuVall, Mariam T. Nawas, Emily Dworkin, Geoffrey D. Wool, Sandeep Gurbuxani, Carrie Fitzpatrick, Jeremy P. Segal, Peng Wang, Michael W. Drazer
Publikováno v:
Haematologica, Vol 108, Iss 8 (2023)
Externí odkaz:
https://doaj.org/article/1d4372d7237e4993adbe87d1b89ac577
Autor:
Stanley I. Gutiontov, William Tyler Turchan, Liam F. Spurr, Sherin J. Rouhani, Carolina Soto Chervin, George Steinhardt, Angela M. Lager, Pankhuri Wanjari, Renuka Malik, Philip P. Connell, Steven J. Chmura, Aditya Juloori, Philip C. Hoffman, Mark K. Ferguson, Jessica S. Donington, Jyoti D. Patel, Everett E. Vokes, Ralph R. Weichselbaum, Christine M. Bestvina, Jeremy P. Segal, Sean P. Pitroda
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Immune checkpoint blockade (ICB) improves outcomes in non-small cell lung cancer (NSCLC) though most patients progress. There are limited data regarding molecular predictors of progression. In particular, there is controversy regarding the r
Externí odkaz:
https://doaj.org/article/82195ffa5c7b45b097938796d4698839
Autor:
Jonathan A. Trujillo, Jason J. Luke, Yuanyuan Zha, Jeremy P. Segal, Lauren L. Ritterhouse, Stefani Spranger, Karen Matijevich, Thomas F. Gajewski
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Background While cancer immunotherapies including checkpoint blockade antibodies, adoptive T cell therapy, and even some vaccines have given rise to major clinical responses with durability in many cases, a subset of patients who initially r
Externí odkaz:
https://doaj.org/article/18fcb395b64e40eab26042c46fe4e356
Autor:
Misha C. Tran, Garth W. Strohbehn, Theodore G. Karrison, Sherin J. Rouhani, Jeremy P. Segal, Ardaman Shergill, Philip C. Hoffman, Jyoti D. Patel, Marina C. Garassino, Everett E. Vokes, Christine M. Bestvina
Publikováno v:
Clinical Lung Cancer. 24:e117-e121
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16641b0206eeb48ca714ee08220bc5fe
https://doi.org/10.1016/j.cllc.2023.01.003
https://doi.org/10.1016/j.cllc.2023.01.003
Autor:
Sean P. Pitroda, Nikolai N. Khodarev, Lei Huang, Abhineet Uppal, Sean C. Wightman, Sabha Ganai, Nora Joseph, Jason Pitt, Miguel Brown, Martin Forde, Kathy Mangold, Lai Xue, Christopher Weber, Jeremy P. Segal, Sabah Kadri, Melinda E. Stack, Sajid Khan, Philip Paty, Karen Kaul, Jorge Andrade, Kevin P. White, Mark Talamonti, Mitchell C. Posner, Samuel Hellman, Ralph R. Weichselbaum
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-8 (2018)
The oligometastasis hypothesis suggests certain metastases are limited in extent and curable with focal therapies. Here they identify three integrated molecular subtypes of colorectal cancer liver metastasis, which complement clinical risk stratifica
Externí odkaz:
https://doaj.org/article/22f79936b0e641648e56509a01ce8a84
Autor:
Michael W. Drazer, Sabah Kadri, Madina Sukhanova, Sushant A. Patil, Allison H. West, Simone Feurstein, Dalein A. Calderon, Matthew F. Jones, Caroline M. Weipert, Christopher K. Daugherty, Adrián A. Ceballos-López, Gordana Raca, Mark W. Lingen, Zejuan Li, Jeremy P. Segal, Jane E. Churpek, Lucy A. Godley
Publikováno v:
Blood Advances, Vol 2, Iss 2, Pp 146-150 (2018)
Abstract: Next-generation sequencing (NGS)–based targeted gene capture panels are used to profile hematopoietic malignancies to guide prognostication and treatment decisions. Because these panels include genes associated with hereditary hematopoiet
Externí odkaz:
https://doaj.org/article/9d39cfe2ed3a40e9bed4f702d8809afc
Autor:
Sabah Kadri, Jimmy Lee, Carrie Fitzpatrick, Natalie Galanina, Madina Sukhanova, Girish Venkataraman, Shruti Sharma, Brad Long, Kristin Petras, Megan Theissen, Mei Ming, Yuri Kobzev, Wenjun Kang, Ailin Guo, Weige Wang, Nifang Niu, Howard Weiner, Michael Thirman, Wendy Stock, Sonali M. Smith, Chadi Nabhan, Jeremy P. Segal, Pin Lu, Y. Lynn Wang
Publikováno v:
Blood Advances, Vol 1, Iss 12, Pp 715-727 (2017)
Abstract: Ibrutinib has generated remarkable responses in patients with chronic lymphocytic leukemia (CLL), including those with an unfavorable cytogenetic profile. However, patients develop resistance, with poor outcomes and no established treatment
Externí odkaz:
https://doaj.org/article/637796cbfd31417ebb804451e9532aa2
Autor:
Vidya Balagopal, Andrew Hantel, Sabah Kadri, George Steinhardt, Chao Jie Zhen, Wenjun Kang, Pankhuri Wanjari, Lauren L Ritterhouse, Wendy Stock, Jeremy P Segal
Publikováno v:
PLoS ONE, Vol 14, Iss 10, p e0224097 (2019)
Improved systems for detection of measurable residual disease (MRD) in acute myeloid leukemia (AML) are urgently needed, however attempts to utilize broad-scale next-generation sequencing (NGS) panels to perform multi-gene surveillance in AML post-in
Externí odkaz:
https://doaj.org/article/4e003646ec644bfb9cfe7194a95a5ed0
Autor:
Thomas D. Lee, Dara L. Aisner, Marjorie Parker David, Celeste C. Eno, Jeffrey Gagan, Christopher D. Gocke, Natalya V. Guseva, Lisa Haley, Audrey N. Jajosky, Daniel Jones, Mahesh M. Mansukhani, Pawel Mroz, Sarah S. Murray, Kimberly J. Newsom, Vera Ashley Paulson, Somak Roy, Chase Rushton, Jeremy P. Segal, T. Niroshini Senaratne, Alexa J. Siddon, Petr Starostik, Jessica A. G. Van Ziffle, David Wu, Rena R. Xian, Sophia Yohe, Annette S. Kim
Publikováno v:
Blood Advances.
While molecular testing of hematologic malignancies is now standard of care, there is variability in practice and testing capabilities between different academic laboratories, with common questions arising on how to best meet clinical expectations. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::466997e7f0665dda7f860d141b300963
https://doi.org/10.1182/bloodadvances.2023010149
https://doi.org/10.1182/bloodadvances.2023010149
Autor:
Tjalling Bosse, Brooke E. Howitt, Vincent T.H.B.M. Smit, Flora E. van Leeuwen, Christi J. van Asperen, Matti A. Rookus, Harry Hollema, Rutika Puranik, Jeremy P. Segal, Maaike P.G. Vreeswijk, Cornelis D. de Kroon, Lauren L. Ritterhouse, Marthe M. de Jonge
Class 4/5 mutations and Tumor Mutational Burden stratified by loss of heterozygosity status.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b6554e3d74b2a412bff760bc43f3ef6
https://doi.org/10.1158/1078-0432.22471688.v1
https://doi.org/10.1158/1078-0432.22471688.v1
